Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigilanol Tiglate + Pembrolizumab in Advanced Melanoma
NCT04834973Phase 2Terminated
- Sponsor
- QBiotics Group Limited
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tigilanol tiglate in melanoma, sponsored by QBiotics Group Limited. Started May 2021; status: terminated.
02
Drugs
tigilanol tiglate
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04834973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834973.